期刊文献+

改良MINE方案治疗侵袭性NK细胞白血病和T细胞淋巴瘤继发噬血细胞综合征3例并文献复习

Hemophagocytic syndrome secondary to invasive NK cell leukemia and T-cell lymphoma treated with the modified MINE protocol:report of three cases and literature review
原文传递
导出
摘要 淋巴瘤相关噬血细胞综合征病情凶险,进展迅速,特别在NK/T细胞淋巴瘤多见。MINE方案为侵袭性非霍奇金淋巴瘤挽救性治疗方案。西安交通大学第一附属医院应用改良MINE方案治疗3例继发于侵袭性NK细胞白血病和T细胞淋巴瘤的噬血细胞综合征患者,初步显示该方案对NK/T细胞淋巴瘤的疗效以及对继发噬血细胞综合征炎症状态的控制和良好的耐受性。 Lymphoma-associated hemophagocytic syndrome is aggressive with rapid progression,particularly in NK/T cell lymphoma.The MINE regimen is a salvage treatment for aggressive non-Hodgkin lymphoma.In our center,the modified MINE regimen was applied to treat three patients with hemophagocytic syndrome secondary to aggressive NK cell leukemia and T-cell lymphoma.The modified MINE regimen showed good efficacy against NK/T cell lymphoma,control of the inflammatory state of secondary hemophagocytic syndrome,and good tolerability.
作者 吴迪 李淼静 李瑶 逯彤霞 付璐瑶 贺鹏程 Wu Di;Li Miaojing;Li Yao;Lu Tongxia;Fu Luyao;He Pengcheng(Department of Hematology,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China;Department of Hematology and Oncology,Nuclear Industry 417 Hospital,Xi'an 710600,China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2024年第6期599-601,共3页 Chinese Journal of Hematology
基金 陕西省重点研发计划项目资助(2022SF-008)。
  • 相关文献

参考文献3

二级参考文献14

  • 1周生余,石远凯,何小慧,张频,董梅,黄鼎智,杨建良,张长弓,刘鹏,杨晟,冯奉仪.DICE方案治疗复发或耐药中高度恶性非霍奇金淋巴瘤[J].癌症,2005,24(4):465-469. 被引量:29
  • 2Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimen for advanced non-Hodgkin's lymphoma [J]. N Engl J Med, 1993,328(14): 1002-1006.
  • 3Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) [J]. Blood,1988,71 ( 1 ): 117-122.
  • 4Coleman M, Leonard J, Shuster MW, et al. DICE(dexamethasone, ifosfamide, cisplatine, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin'slymphoma (NHL) [J]. Eur J Haematol, 2001,64:41-45.
  • 5Wilder DD, Ogden JL, Jain VK, et al. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma [J]. Clin Lymphoma, 2001,1 (4): 285-292.
  • 6Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase Ⅱ trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas [ J ]. Ann Oncol, 1995,6 (6): 609-611.
  • 7The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma [J]. N Engl J Med, 1993,329(14):987-993
  • 8Mayer J, Vasova I, Koristek Z, et al. Ifosfamide- and etoposidebased chemotherapy as salve and mobilizing regimens for poorprognosis lymphoma [ J ]. Eur J Haematol Suppl, 2001,64: 21 -27.
  • 9Emmanouilides C, Lill M, Telatar M, et al. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma [J]. Clin Lymphoma, 2002,3 (2): 111 - 116.
  • 10黄慧强,文海军.《ECSIT基因V140A突变在结外NK/T细胞淋巴瘤中诱发过度炎症并引起“噬血综合症”》解读[J].临床血液学杂志,2018,31(3):329-331. 被引量:16

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部